AIM AIM ImmunoTech

AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series

AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Wednesday, July 12th at 11:00 AM ET

OCALA, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that of AIM ImmunoTech and at AIM ImmunoTech will participate in the on Wednesday, July 12, 2023 at 11:00 AM ET.

A of the presentation will be available on the page of the Company’s website (). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit  and connect with the Company on , , and .



Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
EN
05/07/2023

Underlying

AIMAIM ImmunoTech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Resumes Trading on NYSE American

AIM ImmunoTech Resumes Trading on NYSE American Company trading under the ticker “AIM” NYSE American effective at the start of trading today, Tuesday, June 17th OCALA, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that its common stock has resumed trading on the NYSE American under the symbol "AIM" and CUSIP 00901B303, effective at the start of trading today, June 17, 2025. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of ...

June 17, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing T...

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen® Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (OTC Pink: AIMID) (“AIM” or the “Company”) today announced the United States Patent and Trademark Office has granted U.S. patent No. 12312376, titled “Therapeutic Double Stranded RNA and Methods for Producing the Same.” The patent expires January 25, 2041. T...

June 12, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the Company's common stock on the NYSE American. The NYSE Regulation staff determined that the Company's common stock was now trading above the threshold of low selling price issues as further...

June 12, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced a reverse stock split (“Reverse Stock Split”) of its shares at a ratio of 1-for-100. The Reverse Stock Split will take effect at market open tomorrow, June 12, 2025. The Company’s ticker symbol on the OTC Pink will be AIMID for 20 trading days, including the effective date. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable th...

June 11, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at...

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists OCALA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (OTC Pink: AIMI) (“AIM” or the “Company”) today announced the presentation of clinical trial data involving AIM’s drug Ampligen by Pawel Kalinski, MD, PhD, at the recent held May 3-7, 2025, in Honolulu, HI. The paper, titled “Systemic Infusion of dsRNA (Rintatolimod) plus IFN Promotes Selective Influx of CTLs (but not Treg) into the TME — Counteracting Chemokine Heterogeneity of...

May 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch